Synaptogenesis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
6 May 1986 – USS Ray, USS Archerfish and USS Hawkbill meet and surface together at the Geographic North Pole. First three-submarine surfacing at the Pole. 19 May 1987 – HMS Superb joined USS Billfish and USS Sea Devil at the North Pole. March 2007 – USS Alexandria participated in the Joint US Navy/Royal Navy Ice Exercise 2007 (ICEX-2007) in the Arctic Ocean with the Trafalgar-class submarine HMS Tireless. March 2009 – USS Annapolis took part in Ice Exercise 2009 to test submarine operability and war-fighting capability in Arctic conditions.
The use of trapezoidal rule in AUC calculation was known in literature by no later than 1975, in J.G. Wagner's Fundamentals of Clinical Pharmacokinetics. A 1977 article compares the "classical" trapezoidal method to a number of methods that take into account the typical shape of the concentration plot, caused by first-order kinetics. Notwithstanding the above knowledge, a 1994 Diabetes Care article by Mary M. Tai entitled "A Mathematical Model for the Determination of Total Area Under Glucose Tolerance and Other Metabolic Curves" purports to have independently discovered the trapezoidal rule. In Tai's response to the later letters to the editors, she explained that the rule was new to her colleagues, who relied on grid-counting. Tai's paper has been discussed as a case of scholarly peer review failure. Despite the number of mathematically superior numerical integration schemes (such as those outlined in Wagner & Ayres 1977), the trapezoidal rule remains the convention for AUC calculation. Later focus on improving the accuracy of AUC calculation shifted from improving the method to improving the sampling scheme. An example is a 2019 algorithm known as OTTER: it performs a fit onto sum of exponentials curve for the input data but only uses it to suggest better sample times by finding more highly sloped periods.
The operating principle of CCC equipment requires a column consisting of a tube coiled around a bobbin. The bobbin is rotated in a double-axis gyratory motion (a cardioid), which causes a variable g-force to act on the column during each rotation. This motion causes the column to see one partitioning step per revolution and components of the sample separate in the column due to their partitioning coefficient between the two immiscible liquid phases. "High-performance" countercurrent chromatography (HPCCC) works in much the same way as HSCCC. A seven-year research and development process produced HPCCC instruments that generated 240 g's, compared to the 80 g's of the HSCCC machines. This increase in g-force and larger bore of the column has enabled a ten-fold increase in throughput, due to improved mobile phase flow rates and a higher stationary phase retention. Countercurrent chromatography is a preparative liquid chromatography technique, however with the advent of the higher-g HPCCC instruments it is now possible to operate instruments with sample loadings as low as a few milligrams, whereas in the past hundreds of milligrams had been necessary. Major application areas for this technique include natural product purification and drug development.
=== Other chalcogenide derivatives === Technetium forms a dioxide, disulfide, diselenide, and ditelluride. An ill-defined Tc2S7 forms upon treating pertechnate with hydrogen sulfide. It thermally decomposes into disulfide and elemental sulfur. Similarly the dioxide can be produced by reduction of the Tc2O7. Unlike the case for rhenium, a trioxide has not been isolated for technetium. However, TcO3 has been identified in the gas phase using mass spectrometry.
== In cardiovascular diseases == HSP70 is a chaperone with ubiquitous presence. It is crucial in the cardiovascular system. HSP70 normally aids in protein folding and aggregation; when present in the cell, functioning as an anti-inflammatory molecule; however, under stress conditions, it occurs in the extracellular milieu, where it is involved in inducing inflammatory pathways and contributes to disease pathogenesis. It is well established that intracellular HSP70 (iHSP70) levels play a protective role, whereas extracellular HSP70 (eHSP70) levels in circulating blood are linked to pathophysiology in vasculature, which results in a variety of cardiovascular illnesses. HSP70 homologues identified in human cytosol includes HSPA1A, HSPA1B, HSPA1L, HSPA12B, HSPA13, HSPA14 whereas HSPA9 in mitochondria. HSP70 acts as a damage-associated molecular pattern (DAMP) and activates innate immune response, which is involved in cardiovascular disease progression. The chaperone protein acts as auto antigen in atherosclerosis. Increased oxidative stress causes the formation of high-density oxidized LDL, the first event in the formation of plaque. This activates HSP70 and its promoter in the endothelial and smooth muscle cells, which contributes to atherosclerosis by inducing JAK/STAT pathway expression. HSP70 is linked to high blood pressure. HSPA1A, HSPA1B, and HSPA1L are three genes in humans that encode HSP70, and their polymorphism is linked to the onset of high blood pressure and cardiovascular disease.
Sources: en.wikipedia.org
Through most of the European winter months it was based in Antwerp. In late March 1945 the Rhodesian fighters formed part of the force tasked with protecting the descending Allied paratroopers during Field-Marshal Montgomery's crossing of the Rhine. During April the squadron operated over Hanover and the northern Netherlands. No. 44 Squadron, meanwhile, embarked on bombing raids on targets as far away as Gdynia and Königsberg in East Prussia, as well as towns and cities closer to Berlin such as Dresden, Emden and Leipzig. Its last bombing operation was a raid on the Berghof, Hitler's residence, near Berchtesgaden in Bavaria on 25 April 1945. After Germany surrendered on 7 May, ending the war in Europe, No. 44 Squadron was one of many units selected to evacuate British prisoners of war home from the continent.
== External links == Histology image: 08201loa – Histology Learning System at Boston University – "Connective Tissue: unilocular (white) adipocytes " Histology image: 04901lob – Histology Learning System at Boston University – "Connective Tissue: multilocular (brown) adipocytes"
Congestive heart failure AIDS Chronic obstructive pulmonary disease Chronic kidney disease Cachexia can happen in late stages of diseases like cystic fibrosis, multiple sclerosis, motor neuron disease, Parkinson's disease, dementia, tuberculosis, multiple system atrophy, mercury poisoning, Crohn's disease, trypanosomiasis, rheumatoid arthritis, celiac disease, and other diseases that affect the entire body.
Several methods have been proposed for PET-MRI attenuation coefficient, including machine learning, algorithms to directly estimate attenuation coefficients from the MRI or emission data, and atlas-based approaches (where the MRI scan is co-registered with a database of CT images). While attenuation-corrected images are generally more faithful representations, the correction process is itself susceptible to significant artifacts. As a result, both corrected and uncorrected images are often reconstructed and read together. 2D/3D reconstruction: Early PET scanners had only a single ring of detectors, hence the acquisition of data and subsequent reconstruction was restricted to a single transverse plane. More modern scanners now include multiple rings, essentially forming a cylinder of detectors. There are two approaches to reconstructing data from such a scanner:
On June 28, 2017, The Walt Disney Company, ABC's parent company, paid at least US$177 million to settle the lawsuit. Counsel for BPI stated that this was at that time the largest amount ever paid in a media defamation case in the United States. The product is regulated in different manners in various regions. In the US, the product is allowed to be used in ground beef, and it can be used in other meat products such as beef-based processed meats. The use of ammonium hydroxide as an anti-microbial agent is approved by the Food and Drug Administration, and is included on the FDA's list of GRAS (generally recognized as safe) procedures, and is used in similar applications for numerous other food products, including puddings and baked goods. The product is not allowed in Canada due to the presence of ammonia, and is banned for human consumption in the European Union. Some consumer advocacy groups have promoted the elimination of the product or for mandatory disclosure of additives in beef, while others have expressed concerns about plant closures that occurred after the product received significant news media coverage. In December 2018, pink slime was reclassified as "ground beef" by the Food Safety and Inspection Service of the United States Department of Agriculture.
Sources: en.wikipedia.org
== Society and culture == Depictions of heart attacks in popular media often include collapsing or loss of consciousness which are not common symptoms; these depictions contribute to widespread misunderstanding about the symptoms of myocardial infarctions, which in turn contributes to people not getting care when they should.
György Kéri (Hungarian: [ˈɟørɟ ˈkeːri]; January 11, 1950 – July 20, 2016) was a Hungarian biochemist, professor and Doctor of Biological Sciences (D.Sc.). His major field of research was signal transduction therapy, and he participated in the development of novel drug discovery technologies and drug candidates that entered the clinical development process.
=== Diet === Vitamin A, also known as retinoids, benefits the skin by normalizing keratinization, downregulating sebum production, which contributes to acne, and reversing and treating photodamage, striae, and cellulite. Vitamin D and analogues are used to downregulate the cutaneous immune system and epithelial proliferation while promoting differentiation. Vitamin C is an antioxidant that regulates collagen synthesis, forms barrier lipids, regenerates vitamin E, and provides photoprotection. Vitamin E is a membrane antioxidant that protects against oxidative damage caused most commonly in skin by UV rays.
== Target == ω-Grammotoxin SIA is a 36 amino acid residue protein toxin from spider venom that inhibits P, Q, and N-type voltage-gated calcium channels in neurons. It binds to the channels with high affinity (if closed). It also binds to potassium channels but with lower affinity than to the calcium channels. The toxin binding site has high affinity when channels are in closed states and low affinity when channels are activated. (4)
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.